More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Liraglutide [204656-20-2]
Chemical Structure
Chemical Structure
Chemical Structure

Liraglutide [204656-20-2]

Research Use Only
AG-CP3-0034
AdipoGen Life Sciences
CAS Number204656-20-2
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight3751.2
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Liraglutide
  • Delivery Days Customer
    10
  • CAS Number
    204656-20-2
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C172H265N43O51
  • Molecular Weight
    3751.2
  • Scientific Description
    Chemical. CAS: 204656-20-2. Formula: C172H265N43O51. MW: 3751.2. Synthetic. Long-acting acylated glucagon-like peptide-1 (GLP-1) receptor agonist. Antidiabetic and antiobesity agent used clinically to treat type 2 diabetes mellitus. Binding to GLP-1R, activates AMP-activated protein kinase, consequently stimulates insulin secretion in pancreatic beta cells and suppresses glucagon secretion in a glucose-dependent manner. Improves control of blood glucose and consequently modulates appetite and body weight. Inhibits beta cell apoptosis and improves beta cell mass. Shown to ameliorate glycometabolism and insulin resistance through the upregulation of GLUT4. Neuroprotective. Prevents neurodegenerative processes in pathologies such as Alzheimers and Parkinsons Disease. Anti-inflammatory agent. Exerts cardioprotective roles via activating prosurvival pathways and suppressing inflammation. Anti-pyroptotic by inhibiting TNF-alpha and hypoxia-induced inflammasome activation. Anticancer agent. Inhibited proliferation and induced apoptosis in cancer cell lines. Shown to inhibit osteoclastogenesis. - Long-acting acylated glucagon-like peptide-1 (GLP-1) receptor agonist. Antidiabetic and antiobesity agent used clinically to treat type 2 diabetes mellitus. Binding to GLP-1R, activates AMP-activated protein kinase, consequently stimulates insulin secretion in pancreatic beta cells and suppresses glucagon secretion in a glucose-dependent manner. Improves control of blood glucose and consequently modulates appetite and body weight. Inhibits beta cell apoptosis and improves beta cell mass. Shown to ameliorate glycometabolism and insulin resistance through the upregulation of GLUT4. Neuroprotective. Prevents neurodegenerative processes in pathologies such as Alzheimers and Parkinsons Disease. Anti-inflammatory agent. Exerts cardioprotective roles via activating prosurvival pathways and suppressing inflammation. Anti-pyroptotic by inhibiting TNF-alpha and hypoxia-induced inflammasome activation. Anticancer agent. Inhibited proliferation and induced apoptosis in cancer cell lines. Shown to inhibit osteoclastogenesis.
  • SMILES
    O=C([C@H](CC(C)C)N([H])C([C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C([C@H](C)N([H])C([C@H]([C@@H](C)CC)N([H])C([C@H](CC3=CC=CC=C3)N([H])C([C@H](CCC(O)=O)N([H])C([C@H](CCCCN([H])C(CC[C@@H](C(O)=O)N([H])C(CCCCCCCCCCCCCCC)=O)=O)N([H])C([C@H](C)N([H])C([C@H](C)N([H])C([C@H](CCC(N([H])[H])=O)N([H])C(CN([H])C([C@H](CCC(O)=O)N([H])C([C@H](CC(C)C)N([H])C([C@H](CC(C=C4)=CC=C4O)N([H])C([C@H](CO)N([H])C([C@H](CO)N([H])C([C@H](C(C)C)N([H])C([C@H](CC(O)=O)N([H])C([C@H](CO)N([H])C([C@H]([C@@H](C)O)N([H])C([C@H](CC5=CC=CC=C5)N([H])C([C@H]([C@@H](C)O)N([H])C(CN([H])C([C@H](CCC(O)=O)N([H])C([C@H](C)N([H])C([C@H](CC6=CN=CN6[H])N([H])[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N([H])[C@H](C(N([H])[C@H](C(N([H])CC(N([H])[C@H](C(N([H])CC(O)=O)=O)CCCN([H])/C(N([H])[H])=N/[H])=O)=O)CCCN([H])/C(N([H])[H])=N/[H])=O)C(C)C
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men: H. Agerso, et al.; Diabetologia 45, 195 (2002)
  • The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice: B. Rolin, et al.; Am. J. Physiol. Endocrinol. Metab. 283, E745 (2002)
  • The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro: S. Bregenholt, et al.; BBRC 330, 577 (2005)
  • Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog: J. Meece; Pharmacotherapy 29, 33S (2009) (Review)
  • The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease: P.L. McClean, et al.; J. Neurosci. 31, 6587 (2011)
  • Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection: C. Hoelscher; CNS Drugs 26, 871 (2012) (Review)
  • Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice: L.N. Chen, et al.; Int. J. Mol. Med. 32, 892 (2013)
  • Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease: P.L. McClean & C. Hoelscher; Neuropharmacol. 76, 57 (2014)
  • Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism: N.M. Krasner, et al.; PLoS One 9, e97554 (2014)
  • Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes: M. Garg, et al.; Diabetes Obes. Metab. 19, 1306 (2017)